Alzinova Team

Chief Executive Officer since 2024

Tord brings over 15 years of extensive experience in senior leadership roles within the pharmaceutical industry. His expertise encompasses the entire pharmaceutical value chain, from initial discovery to regulatory approval and product launch.

Through his career Tord held various high-level positions at LEO Pharma, including Vice President & Head of Global Clinical Development, President and Japan Representative Director and Vice President of R&D Asia-Pacific.

Most recently,Tord worked as a senior consultant in the biotechnology, medical technology, and pharmaceutical sectors.

Tord’s diverse background in international pharmaceutical leadership, coupled with his experience across multiple therapeutic areas and global markets, positions him as a seasoned executive in the industry.

Shareholdings *): 96,000 shares
Warrants **): 1,000,000

Education: M.Sci in Molecular Biology and a PhD in Immunology from Lund University

Other assignments: –

Chief Scientific Officer since 2015

Anders is one of Alzinova’s co-founders and was also CEO of the Company during a transitional period. He has extensive experience in protein research with an emphasis on protein stability and folding.

Anders has since 2007 worked with neurotoxic peptide aggregates, which led to the development of ALZ-101 and ALZ-201. He is also a co-inventor of Alzinova’s AβCC technology and has been a deputy board member since 2011.

Shareholdings *): 151,972 shares
Warrants **): 500,000

Education: PhD in Chemistry

Other assignments: –

Chief Financial Officer since 2024

Erik has more than 25 years of experience within international finance and business administration in different sectors. His experience includes financial positions within Swedbank Robur, CFO and CEO at Dunross & Co AB, a privately owned investment company, and CEO at Reguity Group AB. Erik has also experience as interim Chief Financial Officer from several companies.

Shareholdings *): 60,000
Warrants **): 500,000

Education: MSc in Business Administration from Gothenburg School of Business, Economics and Law at the University of Gothenburg

Other assignments: Interim CFO at Medfield Diagnostics AB, Interim CFO at Shortcut Media AB

Intellectual Property Officer since 2021

Ann-Sofie Sternås has more than 25 years of experience in IP/patent matters from the pharmaceutical industry. She has an in-depth understanding and knowledge of IP strategic matters, with a heavy focus on the US legislation, particularly IP matters in the interface between patent legislation and regulatory law. Ann-Sofie has previously worked at AstraZeneca and Pharmacia on IP-related matters from a global perspective, including more than 10 years in the IP litigation of several blockbuster drugs. She has also worked at the investment company Karolinska Development AB.

Shareholdings: –

Education: Authorized European Patent Attorney; Authorized Swedish Patent Attorney. M. Sc. Chemistry education from Royal Institute of Technology

Other assignments: Head of IP in several Swedish pharma/biotech companies.

Vice President R&D Projects since 2021

Stefan has 25 years experience of drug discovery and development. He has worked as a pre-clinical research manager and early clinical project leader to bring compounds for clinical testing and beyond. Stefan worked at AstraZeneca in different project leading and managerial roles in research and development. He also works as a senior consultant supporting smaller biotech and drug development companies.

Shareholdings *): 29,660 shares and 60,051 shares through company
Warrants **): 250,000

Education: MSc Chemical Engineering, PhD Molecular Biology

Other assignments: CEO, ESP Life Science Consulting AB.

Business Development Director since 2023

Sebastian has 15 years of experience from pharmaceutical R&D and clinical development, CRO:s and GMP production of APIs (Active Pharmaceutical Ingredients). He has extensive experience in startups and business development. Before joining Alzinova he has been Chief Operating Officer at SWIPP AB, project manager and Key Account Manager at Polypeptide Group and Business development manager at Solve R&C.

Shareholdings *): 110,061 through companies
Warrants **): 250,000

Education: MSc in Chemistry, PhD in Molecular Biophysics, MBA, Certified Board Member.

Other assignments: Board member of Bulb Intelligence AB, Tyto Competitive Intelligence Solutions AB and Scientific Intelligence Consulting Öresund AB.

Clinical Project Manager since 2023

Karin has over 30 years of experience in clinical R&D including clinical project and study management. She has previously worked both in large clinical organizations and in a start-up biopharma company, InDex Pharma.

Shareholdings *): 2,880
Warrants **): 250,000

Education: RN

Other assignments: –

Head of Regulatory Affairs since 2022

Margareth Jorvid has over 30 years of experience in Regulatory Affairs and has worked at the Swedish Medical Products Agency (MPA) as well as in local and global roles for large and small pharmaceutical companies, such as Roussel Nordiska, Hoechst Marion Roussel (Stockholm and Paris, France) and Neopharma. Since 2006, consultant in regulatory affairs and QA for pharmaceuticals, advanced therapies and medical devices through her company Methra Uppsala AB, LSM group. She is a member and honorary member of TOPRA (Organisation for Professionals in Regulatory Affairs), TOPRA Board member 2004-2012 and TOPRA President 2005-2006.

Shareholdings *): 20,052 shares
Warrants **): 250,000

Education: MSc Pharmacy, MSc Medical Technology Regulatory Affairs (MTRA) and MBA

Other assignments: Owner and CEO of Methra Uppsala AB. Board member of Elicera Therapeutics AB.

Executive Assistant & Communications since 2020

Cecilia has over 10 years of experience in the biopharma industry and more than 20 years in administration.

Shareholdings: –

Warrants **): 4,000